MoCRA Check-In: Unknowns Include How US FDA Will Address Potentially Noncompliant Ingredients

If the FDA reviews companies’ product information submitted under the Modernization of Cosmetics Regulations Act of 2022, which is due by 29 December 2023, and denies product listings deemed noncompliant, that could place products containing unapproved color additives and certain drug active ingredients, for example, in violation of the law.

MoCRA Check-In
• Source: Shutterstock

Since my last progress report in June, several important steps have taken place as we move toward the implementation date for the Modernization of Cosmetics Regulations of 2022 (MoCRA). Before getting into these steps, it’s important to highlight what happens on 29 December 2023. On this date, the cosmetic industry, including ingredient suppliers, will become subject to this new law. This includes (1) product listing and facility registration, (2) reporting to FDA of serious adverse events associated with a product, and (3) mandatory safety substantiation for cosmetic products. (Requirements for (1) labeling, (2) good manufacturing practices, (3) fragrance allergen labeling, (4) talc-related rule, and (5) PFAS in cosmetics rule go into effect later.) Just for perspective, 29 December 2023 is not far away and companies should be taking steps now to comply with these new requirements. (Also see "Attorneys On Modernized Cosmetic Regulations And New Litigation Risks" - HBW Insight, 12 January, 2023.)

Since MoCRA was enacted, FDA has posted only four updates on their website, the most recent on 7 August. My discussion here addresses this most recent update proposing Draft Guidance for Industry: Registration and Listing of Cosmetic Product Facilities and Products. (Also see "US FDA Provides Guidance On MoCRA Facility Registration 17 Weeks Before Deadline To Register" - HBW Insight, 8 August, 2023.) This is a very important update since it provides for the mandatory product listing and facility registration required by MoCRA

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation

Cosmetics Consortium Shares Studies With FDA To Build Confidence In Animal Testing Alternatives

 
• By 

By guiding regulators through case studies and mock dossier examples of how to utilize new approach methodologies, the International Collaboration on Cosmetics Safety hopes to counter hesitations in replacing animal tests.

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By 

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.

Little Industry Opposition To FDA Plan To Remove Synthetic Dyes, Or Agreement They’re Unsafe

 

Dyes and colors which FDA says industries agree should no longer be used aren’t unsafe and are currently used only with the agency’s approval, industry stakeholders say. Center for Science in the Public Interest says the dyes are used “in tens of thousands of foods and beverages that are commonly consumed here in the United States.”